Invivyd to Participate at the Jefferies Healthcare Conference
01 juin 2023 07h00 HE
|
Invivyd
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
11 mai 2023 16h01 HE
|
Invivyd
Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data...
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
04 mai 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
25 avr. 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
25 avr. 2023 07h00 HE
|
Invivyd
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial being conducted in Australia, with cohort 1 dosing completeDiscussions are underway with the FDA and global...
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
12 avr. 2023 07h00 HE
|
Invivyd
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
30 mars 2023 16h01 HE
|
Invivyd
WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
23 mars 2023 16h01 HE
|
Invivyd
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term...
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
22 mars 2023 16h30 HE
|
Invivyd
Research published online today in peer-reviewed journal Science Translational MedicineAnalysis of data from a Phase 2/3 COVID-19 prevention study (EVADE) of adintrevimab suggests clinically...
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
16 mars 2023 07h00 HE
|
Invivyd
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...